Today, Prof Ioannis Pallikaris announced the successful completion of the funding cycle permitted the establishment of a Dutch company under the name EYE PCR.
The sole purpose of this initial cycle of funding was to support the research and development of an innovative idea that will eventually lead to the commercialisation of a new product to be used in either cataract or clear lens exchange surgery. The project will evolve over the next 3 years and up to the point of eventually receiving CE mark for the product.
As of the establishment, EYE PCR signed an agreement with the University of Crete, Heraklion, Greece to assume part of the responsibility of running the initial research and development of the product. Moreover, EYE PCR has signed agreement with a manufacturing company to assume part of the responsibility of actually manufacturing the product and with key personnel to prepare for the clinical trial phases of the project that will eventually lead to CE mark application at the end of the project.